Overview

A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)

Status:
Completed

Trial end date:
2005-10-01

Target enrollment:

Participant gender:

Summary

This study was designed to evaluate if subjects who took 600 mg of abacavir and 300 mg of lamivudine once-daily as a single tablet were just as likely to have adverse events compared to subjects who took 300 mg of abacavir and 150 mg of lamivudine administered as separate tablets twice-daily.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Abacavir
Lamivudine